Japan's Ministry Cautions About Personal Import Drugs
This article was originally published in PharmAsia News
Executive Summary
Regarding personal imported drugs, Japan's Ministry of Health, Labor and Welfare put out a precautionary notice on its website, warning of the high risk of adverse effects. MHLW stated that the efficiency and safety of personal import drugs have not been confirmed by Japanese Pharmaceutical Affairs Law, and the possibilities of them containing harmful materials exist. Even for drugs that have been approved by overseas regulatory authorities, MHLW warned about possible adverse effects. MHLW further noted that victims of adverse effects caused by personal import drugs are not covered by Japan's relief system for victims of adverse drug reactions. (Click here for more - Japanese language
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.